耐喹诺酮的耐甲氧西林金黄色葡萄球菌菌株
Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones.
作者信息
Schaefler S
机构信息
Bureau of Laboratories, New York City Department of Health, New York.
出版信息
J Clin Microbiol. 1989 Feb;27(2):335-6. doi: 10.1128/jcm.27.2.335-336.1989.
Abstract
Since January 1988, Staphylococcus aureus strains with a high level of quinolone resistance have been isolated at 17 hospitals and 15 nursing homes in New York City. The majority of these strains were methicillin resistant. The bacteriophage types and susceptibility to other antibiotics were similar to those of quinolone-susceptible strains isolated at the same hospitals.
摘要
自1988年1月以来，纽约市17家医院和15家疗养院分离出了对喹诺酮具有高度耐药性的金黄色葡萄球菌菌株。这些菌株大多数对甲氧西林耐药。其噬菌体类型及对其他抗生素的敏感性与在同一些医院分离出的喹诺酮敏感菌株相似。
相似文献
1
Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones.
J Clin Microbiol. 1989 Feb;27(2):335-6. doi: 10.1128/jcm.27.2.335-336.1989.
2
Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
Antimicrob Agents Chemother. 1989 Apr;33(4):519-21. doi: 10.1128/AAC.33.4.519.
3
Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.
Antimicrob Agents Chemother. 1989 Apr;33(4):593-4. doi: 10.1128/AAC.33.4.593.
4
Staphylococcus aureus resistance to antibiotics and spread of phage types.
Medicina (Kaunas). 2006;42(4):332-9.
5
Ciprofloxacin resistance in methicillin- and gentamicin-resistant Staphylococcus aureus.
Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):622-4. doi: 10.1007/BF01968141.
6
Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in New York health care facilities, 1988. The New York MRSA Study Group.
Am J Public Health. 1990 Jul;80(7):810-3. doi: 10.2105/ajph.80.7.810.
7
Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.
Antimicrob Agents Chemother. 1990 Nov;34(11):2050-4. doi: 10.1128/AAC.34.11.2050.
8
Emergence of gentamicin- and methicillin-resistant Staphylococcus aureus strains in New York City hospitals.
J Clin Microbiol. 1981 Apr;13(4):754-9. doi: 10.1128/jcm.13.4.754-759.1981.
9
Newer agents against methicillin and/or gentamicin-resistant and -susceptible staphylococci.
Chemotherapy. 1989;35(5):333-7. doi: 10.1159/000238691.
10
In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones.
J Antimicrob Chemother. 1988 Oct;22 Suppl D:35-41. doi: 10.1093/jac/22.supplement_d.35.
引用本文的文献
1
and Properties of CUO246, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0092122. doi: 10.1128/aac.00921-22. Epub 2022 Nov 30.
2
Comparison between the effect of Lawsonia inermis and flubendazole on Strongyloides species using scanning electron microscopy.
J Parasit Dis. 2016 Jun;40(2):415-22. doi: 10.1007/s12639-014-0519-2. Epub 2014 Aug 24.
3
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.
Clin Microbiol Rev. 1997 Oct;10(4):781-91. doi: 10.1128/CMR.10.4.781.
4
Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.
Antimicrob Agents Chemother. 1996 Aug;40(8):1835-42. doi: 10.1128/AAC.40.8.1835.
5
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.
Antimicrob Agents Chemother. 1996 May;40(5):1157-63. doi: 10.1128/AAC.40.5.1157.
6
Epidemiology of quinolone resistance: Europe and North and South America.
Drugs. 1995;49 Suppl 2:36-42. doi: 10.2165/00003495-199500492-00007.
7
Lomefloxacin clinical pharmacokinetics.
Clin Pharmacokinet. 1993 Jul;25(1):6-19. doi: 10.2165/00003088-199325010-00002.
8
Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.
Infection. 1993 Mar-Apr;21(2):106-11. doi: 10.1007/BF01710743.
9
A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.
Support Care Cancer. 1994 May;2(3):191-6. doi: 10.1007/BF00417480.
10
Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.
Infection. 1994;22 Suppl 2:S111-21. doi: 10.1007/BF01793575.
本文引用的文献
1
Emergence of gentamicin- and methicillin-resistant Staphylococcus aureus strains in New York City hospitals.
J Clin Microbiol. 1981 Apr;13(4):754-9. doi: 10.1128/jcm.13.4.754-759.1981.
2
Methicillin-resistant Staphylococcus aureus strains in New York City hospitals: inter-hospital spread of resistant strains of type 88.
J Clin Microbiol. 1984 Sep;20(3):536-8. doi: 10.1128/jcm.20.3.536-538.1984.
3
Bacterial resistance to fluoroquinolones.
Rev Infect Dis. 1988 Jan-Feb;10 Suppl 1:S57-63. doi: 10.1093/clinids/10.supplement_1.s57.
4
In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 1986 Feb;29(2):325-6. doi: 10.1128/AAC.29.2.325.
5
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
J Antimicrob Chemother. 1986 Jan;17(1):63-7. doi: 10.1093/jac/17.1.63.
Zotero 插件